27
56
Growth Score
-1 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
239214
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company
Timothy Allen: EVP- InPyo Hong: RA Team Director
About the Company
MedPacto is a genome-based drug discovery and clinical-stage biotechnology company that is pursuing the development of first-in-class therapies to bring new hope to patients suffering from the most challenging diseases such as cancer. Vactosertib, an orally bioavailable small-molecule inhibitor of the TGF-type I receptor (TRI) that is currently in
phase II clinical trials with global pharmaceutical companies such as Merck and AstraZeneca, is the leading drug candidate.
